Methods
We performed a single center IRB approved retrospective chart review of
80 consecutive pediatric allogeneic SCT patients transplanted between
2013 and 2015. Clinical data was reviewed through 2019. Baseline
hyperfiltration status was determined using pre-SCT nuclear medicine
GFR. Hyperfiltration was defined as a GFR≥135 mL/min/1.73
m2, which is the median value used in the
literature.6 A normal GFR was defined as a GFR between
90 and 135 mL/min/1.73 m2. Demographics recorded
included age, gender, primary diagnosis, exposure to chemotherapy prior
to SCT, stem cell source and match, conditioning regimen, and if ex-vivo
T cell depletion was utilized for graft versus host prevention. Outcomes
assessed included AKI, defined as a doubling of creatinine in the first
100 days of transplant, need for renal replacement therapy, and 1 year
event-free survival. In patients who had at least 2 years of follow up,
the outcome of CKD was defined as a creatinine-based estimated
GFR<90 or GFR≥135 mL/min/1.73 m2 at last
follow up. Continuous and categorical data were summarized as median
(interquartile range) and frequency (percent), respectively. Continuous
data were assessed between hyperfiltration (Y/N) patients using a
Wilcoxon rank sum test. Categorical data were compared between
hyperfiltration patients using Fisher’s exact test. A p-value of
<0.05 was considered significant.